179 related articles for article (PubMed ID: 15916899)
1. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum.
Ryu JK; Choi HB; McLarnon JG
Neurobiol Dis; 2005 Nov; 20(2):550-61. PubMed ID: 15916899
[TBL] [Abstract][Full Text] [Related]
2. VEGF receptor antagonist Cyclo-VEGI reduces inflammatory reactivity and vascular leakiness and is neuroprotective against acute excitotoxic striatal insult.
Ryu JK; McLarnon JG
J Neuroinflammation; 2008 May; 5():18. PubMed ID: 18492281
[TBL] [Abstract][Full Text] [Related]
3. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease.
Ryu JK; Kim SU; McLarnon JG
Exp Neurol; 2004 May; 187(1):150-9. PubMed ID: 15081596
[TBL] [Abstract][Full Text] [Related]
4. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro.
Wilms H; Claasen J; Röhl C; Sievers J; Deuschl G; Lucius R
Neurobiol Dis; 2003 Dec; 14(3):417-24. PubMed ID: 14678758
[TBL] [Abstract][Full Text] [Related]
5. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease.
Senatorov VV; Ren M; Kanai H; Wei H; Chuang DM
Mol Psychiatry; 2004 Apr; 9(4):371-85. PubMed ID: 14702090
[TBL] [Abstract][Full Text] [Related]
6. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.
Hughes PE; Alexi T; Williams CE; Clark RG; Gluckman PD
Neuroscience; 1999; 92(1):197-209. PubMed ID: 10392842
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum.
Lehrmann E; Molinari A; Speciale C; Schwarcz R
Exp Brain Res; 2001 Dec; 141(3):389-97. PubMed ID: 11715084
[TBL] [Abstract][Full Text] [Related]
8. Chemical and anatomical changes in the striatum and substantia nigra following quinolinic acid lesions in the striatum of the rat: a detailed time course of the cellular and GABA(A) receptor changes.
Brickell KL; Nicholson LF; Waldvogel HJ; Faull RL
J Chem Neuroanat; 1999 Oct; 17(2):75-97. PubMed ID: 10585160
[TBL] [Abstract][Full Text] [Related]
9. Minocycline in phenotypic models of Huntington's disease.
Bantubungi K; Jacquard C; Greco A; Pintor A; Chtarto A; Tai K; Galas MC; Tenenbaum L; Déglon N; Popoli P; Minghetti L; Brouillet E; Brotchi J; Levivier M; Schiffmann SN; Blum D
Neurobiol Dis; 2005 Feb; 18(1):206-17. PubMed ID: 15649711
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand.
Taylor DL; Jones F; Kubota ES; Pocock JM
J Neurosci; 2005 Mar; 25(11):2952-64. PubMed ID: 15772355
[TBL] [Abstract][Full Text] [Related]
11. Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats.
Ananth C; Gopalakrishnakone P; Kaur C
Hippocampus; 2003; 13(3):375-87. PubMed ID: 12722978
[TBL] [Abstract][Full Text] [Related]
12. Nomega-nitro-L-arginine, a nitric oxide synthase inhibitor, antagonizes quinolinic acid-induced neurotoxicity and oxidative stress in rat striatal slices.
Santamaría D; Espinoza-González V; Ríos C; Santamaría A
Neurochem Res; 1999 Jul; 24(7):843-8. PubMed ID: 10403623
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies.
Santamaría A; Salvatierra-Sánchez R; Vázquez-Román B; Santiago-López D; Villeda-Hernández J; Galván-Arzate S; Jiménez-Capdeville ME; Ali SF
J Neurochem; 2003 Jul; 86(2):479-88. PubMed ID: 12871589
[TBL] [Abstract][Full Text] [Related]
14. Cellular and subcellular localization of peripheral benzodiazepine receptors after trimethyltin neurotoxicity.
Kuhlmann AC; Guilarte TR
J Neurochem; 2000 Apr; 74(4):1694-704. PubMed ID: 10737628
[TBL] [Abstract][Full Text] [Related]
15. Time course of the neuroprotective effect of transplantation on quinolinic acid-induced lesions of the striatum.
Levivier M; Gash DM; Przedborski S
Neuroscience; 1995 Nov; 69(1):43-50. PubMed ID: 8637631
[TBL] [Abstract][Full Text] [Related]
16. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
17. The 1993 Upjohn Award Lecture. Quinolinic acid induced brain neurotransmitter deficits: modulation by endogenous excitotoxin antagonists.
Jhamandas KH; Boegman RJ; Beninger RJ
Can J Physiol Pharmacol; 1994 Dec; 72(12):1473-82. PubMed ID: 7736338
[TBL] [Abstract][Full Text] [Related]
18. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195.
Choi HB; Khoo C; Ryu JK; van Breemen E; Kim SU; McLarnon JG
J Neurochem; 2002 Nov; 83(3):546-55. PubMed ID: 12390516
[TBL] [Abstract][Full Text] [Related]
20. Remote microglial activation in the quinolinic acid model of Huntington's disease.
Töpper R; Gehrmann J; Schwarz M; Block F; Noth J; Kreutzberg GW
Exp Neurol; 1993 Oct; 123(2):271-83. PubMed ID: 8405289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
